Opinion on the use of the revenues of the pharmaceutical industry in France 2016

This statistic shows the results of a survey concerning the payment of dividends by the pharmaceutical industry thanks to the revenues of the innovative treatments reimbursed by the French Social Security in 2016. More than a third of respondents did not at all agree with the idea that the pharmaceutical industry pays dividends to its shareholders with the revenues of expensive innovative treatments reimbursed by Social Security.

Do you agree with the idea that it is normal for the pharmaceutical industry to pay dividends to its shareholders with the revenues of expensive innovative treatments reimbursed by Social Security? *

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

March 2016

Region

France

Survey time period

February 25 - 27, 2016

Number of respondents

1,004 respondents

Age group

15 years and older

Method of interview

Telephone interview

Supplementary notes

* The question was formulated by the source as follows: "The prices of some innovative drugs are rising. In France, for example, recently for hepatitis C, treatment at 40,000 euros has led to the selection of patients: it has only been delivered to the most serious cases.
For each of the following opinions, say: us if you strongly agree, tend to agree, tend to disagree or strongly disagree.
- It is normal for the pharmaceutical industry to pay dividends to its shareholders with income expensive innovative treatments reimbursed by Social Security. "

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Over-the-counter medicine industry in the United Kingdom"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.